Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Randomized, Controlled Open-label Trial to Evaluate the Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Healthy Children Aged 1 to 12 Years and in Their Relatives Living in Lambaréné, Gabon

NCT05130398 is registered in ClinicalTrials.gov with Centre de Recherche Médicale de Lambaréné as lead sponsor.

NCT NCT05130398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05130398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Randomized, Controlled Open-label Trial to Evaluate the Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Healthy Children Aged 1 to 12 Years and in Their Relatives Living in Lambaréné, Gabon
Lead sponsor
Centre de Recherche Médicale de Lambaréné
Phase
Phase 1/2
Overall status
Completed
Start date
April 9, 2021
Completion date
August 9, 2022
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ebola virus disease